The pharmaceutical industry requested for the 1-year delay of the drug price reduction worth of KRW 200 billion

In order to overcome financial difficulties of the pharmaceutical industry caused by the MERS crisis and have new drug development and global expansion according to plan, the Korea Pharmaceutical Manufacturers Association(KPMA) decided to suggest the government to defer the ‘Drug Price Reduction of Real Transaction Price Investigation’ measure for a year.

This is because of concerns that the d...